Application of geniposide in preparation of anti-alopecia and hair-growing medicine
By using gardeniatin and its physiologically acceptable salts or solvates, the side effects and poor efficacy of existing hair loss drugs have been solved, safe and effective hair growth effects have been achieved, and economical for chemotherapy and androgen hair loss have been provided. Affordable solution.
Patent Information
- Application Number
- CN202411249954.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-06
AI Technical Summary
Existing drugs for treating hair loss such as minoxidil and finasteride have side effects and may cause worsening hair loss after discontinuation, lacking safe, effective and affordable alternatives.
Gardeniatin and its physiologically acceptable salts or solvates are used as active ingredients to prepare anti-hair loss and hair growth drugs. By stimulating cell growth and increasing the expression level of related growth factors, it promotes hair growth. It is suitable for cosmetics and care. and beauty products.
Gardeniasin significantly promotes hair growth, is safe and effective, and has no adverse reactions, opening up new uses and providing an affordable option for the treatment of androgenicity and chemotherapy hair loss.
Smart Images

Figure CN119074750A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to the use of geniposide and its physiologically acceptable salts or solvates in the preparation of anti-hair loss and hair growth drugs, and further application in the fields of cosmetics, care products, beauty products, etc. Background Art
[0002] Hair loss refers to the phenomenon of hair falling out. Among them, physiological hair loss is the normal loss of hair in order to maintain the balance between the regression phase and the growth phase; pathological hair loss refers to excessive and abnormal hair loss.
[0003] Hair loss can be divided into two categories based on the presence or absence of scarring and its characteristics. Scarring alopecia is the result of damage to the hair follicles, which are irreversibly damaged and then replaced by fibrous tissue. Some alopecias show a biphasic pattern, that is, scarring is non-scarring in the early stages of the disease, and scarring and permanent hair loss occurs as the disease progresses; non-scarring alopecia is caused by reduced or slowed hair growth (the hair follicles are not irreversibly damaged). Diseases that mainly affect the hair shaft are also considered non-scarring alopecia.
[0004] Hair loss is often influenced by a variety of factors: family history, hereditary hair loss caused by aging is one of the most common causes; hormone changes and health problems, such as pregnancy, childbirth, menopause and thyroid problems, hormone changes may cause permanent or temporary hair loss. Health problems also include immune system related diseases, such as alopecia areata and scalp infections caused by psoriasis, and hair pulling disorders such as trichotillomania; medications and supplements, certain medications, such as those for cancer, arthritis, depression, heart problems, gout and high blood pressure, may have side effects that cause hair loss. After radiation therapy to the head, hair may not regrow; extreme stress events can also cause hair loss, such as after a physical or emotional shock, the hair may be significantly reduced within a few months, but this type of hair loss is usually temporary.
[0005] At present, the two main drugs used to treat hair loss on the market are minoxidil, which is suitable for both men and women. Another drug, finasteride, is only suitable for men. Both drugs have their own side effects. Finasteride mainly works by inhibiting the activity of 5α-reductase and the expression of androgen receptors, so it may cause potential side effects in male sexual function such as loss of libido and impotence. Minoxidil can stimulate the differentiation and proliferation of hair follicle epithelial cells by causing local vasodilation. The use of minoxidil may cause adverse reactions such as irritant dermatitis, allergic contact dermatitis, headache and hypotension. After discontinuation of use, hair loss may occur again, and the hair loss may be aggravated. Therefore, there is an urgent need to find safer, more effective and affordable treatment drugs.
[0006] Gardenia jasminoides (geniposide), also known as geniposide, CAS: 24512-63-8, molecular formula C 17 H 24 O 10 Its aglycone is genipin, which is an iridoid glucoside, mainly found in plants such as Gardenia and Eucommia, has good biological activity, and is an extremely important Chinese medicinal ingredient with great development and utilization value. Its structural formula is:
[0007]
[0008] However, there is no document publicly reporting the application of Gardenia jasminoides and its physiologically acceptable salts or solvates in hair loss and hair growth. Summary of the invention
[0009] One object of the present invention is to provide a use of gardenia glycoside and its physiologically acceptable salt or solvate in the preparation of anti-hair loss and hair growth medicines. The gardenia glycoside and its physiologically acceptable salt or solvate disclosed in the present invention are safe and effective hair growth active substances that can meet the nursing, therapeutic and cosmetic effects. Specifically, the present invention provides the use of gardenia glycoside and its physiologically acceptable salt or solvate in the preparation of anti-hair loss and hair growth medicine preparations; and the use of gardenia glycoside and its physiologically acceptable salt or solvate in the preparation of various cosmetics, care products and beauty products.
[0010] The present invention provides use of gardenia jasminoides and physiologically acceptable salts or solvates thereof in the preparation of anti-hair loss and hair growth medicines.
[0011] Gardenia glycosides promote hair growth in mice with hair plucking. After hair plucking, the hair length and weight of the back hair of the mice were measured on the 14th day of administration. Compared with the model group, gardenia glycosides increased hair length and promoted hair growth, and the effects of gardenia glycosides on hair length and hair weight were better than those of the minoxidil group. In addition, gardenia glycosides can increase the expression level of related growth factor genes, stimulate cell growth, promote cell survival, and thus promote hair growth.
[0012] When preparing a drug for treating diseases related to hair loss, gardenia glycoside and its physiologically acceptable salts or solvates are used as active ingredients, and the drug is applied to a pharmaceutical preparation; the pharmaceutical preparation is applied to prevent, care for and treat thin hair, hair loss and promote hair health and growth.
[0013] The pharmaceutical preparation comprises geniposide and a physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.
[0014] The pharmaceutically acceptable carrier (e.g., a biocompatible material) may optionally include a surfactant, an excipient, a humectant, an emulsifier, a suspending agent, a salt or a buffer for adjusting the osmotic pressure, a colorant, a flavor, a stabilizer, a bactericide, a preservative or other conventional supplements.
[0015] The dosage form of the drug is cream, patch, ointment, cream preparation, gel or spray.
[0016] The dosage form of the drug can also be tablets, granules, capsules, oral liquid preparations, pills, suspensions or dripping pills.
[0017] When treating diseases related to hair loss, Gardenia jasminoides and its physiologically acceptable salts or solvates are used as active ingredients. They can be applied topically to the skin, such as creams, patches, ointments, gels and sprays, etc., or they can be taken orally (i.e., oral preparations), such as tablets, granules, capsules, oral liquid preparations, pills, suspensions, pellets, etc.
[0018] The geniposide and its physiologically acceptable salt or solvate account for 0.1-10 wt % of the total weight of the preparation.
[0019] The medicine of the present invention can be used for preventing and / or treating alopecia after chemotherapy.
[0020] Gardenia glycosides can inhibit alopecia caused by chemotherapeutic agents, resist chemotherapy toxicity and prevent alopecia in chemotherapy-induced alopecia. Hair loss reached its peak on the 5th day after cyclophosphamide injection, and hair growth scores and hair length and weight were measured on the 6th day. Compared with the model group, gardenia glycosides increased hair growth scores and increased hair length and weight in a dose-dependent manner, and gardenia glycosides were more effective than minoxidil at high concentrations.
[0021] The medicine of the present invention can also be used for preventing and / or treating androgenic alopecia.
[0022] Gardenia glycosides can inhibit androgens, stimulate the proliferation of hair follicle papilla cells and hair growth, thereby preventing or treating androgenic alopecia. After daily application of androgen modeling and administration for 14 days, compared with the model group, gardenia glycosides increased hair length and weight in a dose-dependent manner, and the effect was better than minoxidil.
[0023] The drug of the present invention can also be used in cosmetics, care products or beauty products. The cosmetics, care products or beauty products use geniposide and its physiologically acceptable salt or solvate as active ingredients.
[0024] The cosmetics, care products or beauty products can be selected from shampoo, hair conditioner, hair essence, hair oil, hair lotion, scalp cream, hair gel, hair spray, hair mask, eyebrow care solution and the like.
[0025] The drug of the present invention stimulates hair growth; the stimulation of hair growth includes accelerating the natural growth rate of hair, increasing hair length and weight, and promoting the growth of existing hair in a healthy state; the drug stimulates the expression and synthesis of growth factors, stimulates cell growth, promotes cell survival, and promotes hair growth.
[0026] The beneficial effects of the present invention are as follows: the gardenia glycoside and its physiologically acceptable salt or solvate of the present invention can effectively promote hair growth in androgenic and chemotherapy alopecia areas, are safe and effective, and have no adverse reactions; they open up new uses of gardenia glycoside and its physiologically acceptable salt or solvate, and provide a new choice for the preparation of anti-hair loss and hair growth drugs. In addition, the gardenia glycoside and its physiologically acceptable salt or solvate of the present invention can be extracted from plants, have a wide range of sources, are low in cost, and are economical and affordable, and are very convenient to use as drugs for the preparation of androgenic alopecia and chemotherapy alopecia drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is the effect of geniposide on hair length in natural hair growth model mice.
[0028] Figure 2 The effect of geniposide on gross weight in natural hair growth model mice.
[0029] Figure 3 The changes in skin growth factor gene expression induced by geniposide in natural hair growth model mice.
[0030] Figure 4 The effect of gardenia glycoside on hair growth in the cyclophosphamide-induced chemotherapy-induced alopecia C57BL / 6 mouse model.
[0031] Figure 5 To investigate the effect of geniposide on hair length in the cyclophosphamide-induced chemotherapy-induced alopecia C57BL / 6 mouse model.
[0032] Figure 6 To investigate the effect of geniposide on gross weight in the cyclophosphamide-induced chemotherapy-induced alopecia C57BL / 6 mouse model.
[0033] Figure 7 This study is the effect of geniposide on hair length in the testosterone-induced androgenic alopecia C57BL / 6 mouse model.
[0034] Figure 8 The effect of geniposide on gross weight in the testosterone-induced androgenic alopecia C57BL / 6 mouse model. DETAILED DESCRIPTION
[0035] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.
[0036] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0037] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.
[0038] Unless otherwise specified, "%" in the examples refers to mass percentage.
[0039] Example 1 Experimental study on the efficacy of geniposide on the natural hair growth model of C57BL / 6J mice
[0040] 1. Experimental Animals
[0041] The experimental animals were male C57BL / 6J, 7-8 weeks old, weighing 20-24g. C57BL / 6J mice were raised under normal conditions, with a temperature of 25±2℃, a humidity of 50%-70%, and alternating light and dark for 12h each. They were free to eat and drink, and the corncob bedding was changed every two days. The experiment began after they had adapted to the breeding environment for 7 days.
[0042] 2. Drug preparation
[0043] 4% chloral hydrate: weigh 0.8g chloral hydrate and pour into a 20ml centrifuge tube. Add 19.2ml normal saline and dissolve it evenly to prepare a 4% chloral hydrate solution. Prepare and use it immediately.
[0044] Gardenia glycoside topical cream (concentration: 0.5%, 1.0%, 2.0%), is made from the following raw materials:
[0045] Take 50, 100 and 200 parts by weight of gardenia glycoside, 1000 parts by weight of stearic acid, 200 parts by weight of glyceryl stearate, 200 parts by weight of beeswax, 200 parts by weight of palm oil, 600 parts by weight of butylene glycol, 200 parts by weight of ethanol, 4800 parts by weight of water and 2 parts by weight of triethanolamine respectively. According to the above raw material components, the external cream of the present invention is prepared:
[0046] (1) Weigh stearic acid, stearyl glyceride, beeswax, and palm oil in proportion, heat in a water bath until melted, filter, and store at a constant temperature of 70-80°C;
[0047] (2) Weigh butanediol, ethanol, water, and triethanolamine in proportion, add them to the above solution, heat and stir in a water bath at 80° C., and emulsify for 10-20 minutes;
[0048] (3) Add the weighed geniposide raw material and stir until the raw material and the cream are evenly mixed to obtain 0.5%, 1.0%, and 2.0% external creams.
[0049] 3. Establishment of natural hair loss model
[0050] (1) Experimental principle:
[0051] The hair growth of C57BL / 6 mice aged 7-8 weeks is stagnant and in the resting phase, so a natural hair growth model can be constructed. All the resting hairs are removed with wax paper to induce the hair follicles to enter the growth phase in a highly synchronous manner. The hair follicles are morphologically indistinguishable from the spontaneously formed growth phase follicles.
[0052] (2) Specific operations:
[0053] After the mice were weighed, 4% chloral hydrate was intraperitoneally injected at a dose of 10 μl / g BW (body weight). After the mice were anesthetized, the back hair was shaved with a shaver, and the 5.20 cm × 2.60 cm hair removal wax paper was warmed by hand and pasted from behind the ear to the tail along the hair growth direction of the mice. The legs were grasped with the left hand, and the hind legs were placed in the tiger's mouth with the front facing up, and the tail was pressed with the thumb, and the wax paper was quickly torn off from the tail with the right hand against the hair, and the back was wiped with wax removal wet paper.
[0054] Forty male C57BL / 6J mice were randomly divided into a model group, a 0.5% gardenia glycoside group, a 1.0% gardenia glycoside group, a 2.0% gardenia glycoside group, and a 2.5% minoxidil group, with 8 mice in each group.
[0055] 4. Experimental study on the efficacy of geniposide on the natural growth of hair in mice with natural hair loss
[0056] The drug was administered from the first day after hair removal, once a day, for 13 consecutive days. The commercially available minoxidil tincture had a concentration of 5%, which was diluted to 2.5% by adding an equal volume of anhydrous ethanol, and the dosage was 200 μl per head. The model group was smeared with a blank cream without drug; the gardenia glycoside ointment group was administered with a concentration of 0.5%, 1.0%, and 2.0%, and the dosage was 0.2 g / head. Each time the drug was administered, a syringe was used to push out 0.2 ml of the ointment and evenly apply it on the back from the tail to the front.
[0057] On the 14th day after administration, the experimental mice were intraperitoneally injected with 10 μl / g BW 4% chloral hydrate. After the anesthesia of the mice was stable, the hairs were carefully plucking from 6 fixed points on the back of the mice with tweezers. About 10 hairs were plucking each time and placed on a clean white paper. The length was measured with a vernier caliper and the longest value was selected as the record value. The whole measurement process was repeated twice.
[0058] After the hair length measurement is completed, use a shaver to shave the grown hair in the depilatory area, collect it with weighing paper, and weigh the gross weight with a 1 / 100,000 electronic balance.
[0059] Growth factors, as a class of molecules that can promote cell proliferation and differentiation, have an important influence on the growth and development of hair. Growth factors such as IGF1, VEGF, EGF, and HGF can all be secreted by hair papilla cells. EGF can increase the level of β-catenin in the cell nucleus and activate Wnt10b, thereby stimulating the activity and growth of hair follicle outer root sheath cells; HGF is involved in stimulating the growth of mouse hair bulbs and hair shaft elongation; IGF1 can act on hair papilla cells to restore and maintain the potential for hair induction; VEGF participates in the growth and development of hair by forming blood vessels around hair follicles. Therefore, qPCR detection of hair growth-related growth factors was performed on the skin tissue after administration.
[0060] The skin tissue on the back of the mice was removed, RNA was extracted, reverse transcribed into cDNA, and qPCR amplification was performed using the SYBR Green dye method. The ΔΔCt method was used to calculate the Ct value to analyze the changes in the expression levels of growth factor-related genes. The relevant primer sequences are shown in Table 1:
[0061] Table 1 RT-qPCR primer sequences
[0062]
[0063] The relevant qPCR reaction system is shown in Table 2:
[0064] Table 2 RT-qPCR reaction system
[0065]
[0066] The relevant qPCR reaction procedures are shown in Table 3:
[0067] Table 3 qPCR reaction procedure
[0068]
[0069]
[0070] 5. Experimental results
[0071] Hair length results Figure 1 As shown, compared with the model group, the Gardenia glycoside ointment group increased hair length in a dose-dependent manner and promoted hair growth, and the effect of 2.0% Gardenia glycoside was better than that of the positive drug minoxidil group.
[0072] The gross weight result is Figure 2 As shown, compared with the model group, the Gardenia glycoside ointment group increased hair weight in a dose-dependent manner, and the effects of 1.0% and 2.0% Gardenia glycoside were better than those of the positive drug minoxidil group.
[0073] The results of skin growth factor gene expression levels are as follows Figure 3 As shown, compared with the model group, the expression levels of growth factor genes such as IGF1, VEGF, EGF, and HGF in the Gardenia glycoside ointment group were increased, indicating that it can stimulate cell growth, promote cell survival, and promote hair growth.
[0074] In summary, it can be seen that Gardenia glycoside has a significant effect in promoting hair growth in mice.
[0075] Example 2 Experimental evaluation of the efficacy of geniposide on alopecia induced by chemotherapy
[0076] 1. Experimental Animals
[0077] The experimental animals were the same as in Example 1.
[0078] 2. Drug preparation
[0079] The preparation of 4% chloral hydrate and gardenia glycoside ointment is the same as that in Example 1.
[0080] 8mg / ml cyclophosphamide injection (Andaosheng): 0.2g cyclophosphamide is dissolved in 25ml normal saline, vortexed and centrifuged, and injected intraperitoneally into mice after complete dissolution.
[0081] 3. Modeling of chemotherapy-induced hair loss
[0082] (1) Experimental principle:
[0083] The back hair of 7-8 week old C57 male mice was removed. On the 8th day after depilation, the newly formed hair follicles in all the depilated areas entered the growth stage VI. 80 mg / kg of cyclophosphamide was injected intraperitoneally once to induce an increase in apoptotic cells in the rapidly growing hair follicles, causing chemotherapy-induced alopecia in the newly formed hair of the mice.
[0084] (2) Specific operations:
[0085] The depilatory method is the same as in Example 1.
[0086] Forty-eight male C57BL / 6J mice were randomly divided into control group, model group, 0.5% gardenia glycoside group, 1.0% gardenia glycoside group, 2.0% gardenia glycoside group, and 2.5% minoxidil group, with 8 mice in each group.
[0087] On the 8th day after hair removal, the hair entered the growth stage VI, and 80mg / kg of cyclophosphamide injection was injected intraperitoneally at 10μl / g BW, while the control group was injected with solvent saline. On the 5th day after cyclophosphamide injection, hair loss reached its most serious stage.
[0088] 4. Experimental study on the efficacy of geniposide in chemotherapy-induced alopecia model
[0089] The drug was administered from the first day after hair removal, once a day, for 13-14 consecutive days, and the experiment was terminated depending on the hair loss. The minoxidil group was administered at a dose of 200 μl per head. The control group and the model group were smeared with a blank cream without drug; the gardenia glycoside ointment group was administered at a concentration of 0.5%, 1.0%, and 2.0%, and the dosage was 0.2 g / head. Each time the drug was administered, a syringe was used to push out 0.2 ml of the ointment and evenly apply it on the back from the tail to the front.
[0090] On the 13th day of administration, hair loss reached the most serious stage. On the 14th day, the experimental mice were intraperitoneally injected with 10μl / gB.W.4% chloral hydrate. After the mice were anesthetized, photos were taken under standard conditions to record the back skin condition and hair growth of each group of mice and score statistics. Scoring criteria: the proportion of the remaining hair area to the total area of the hair loss area.
[0091] After the hair growth scoring is completed, use tweezers to carefully pick up the hair at 6 fixed locations on the back of the mouse, taking about 10 hairs each time, and place them on a clean white paper. Use a vernier caliper to measure the length and select the longest value as the record value. Repeat the entire measurement process twice.
[0092] After the hair length measurement is completed, use a shaver to shave the grown hair in the depilatory area, collect it with weighing paper, and weigh the gross weight with a 1 / 100,000 electronic balance.
[0093] 5. Experimental results
[0094] Hair growth score results Figure 4 As shown in the figure, compared with the blank control group, the growth score of the model group was significantly reduced, proving that the model was successful. Compared with the model group, the gardenia glycoside ointment group could improve the hair growth score, and the effects of the 1.0% and 2.0% gardenia glycoside groups were better than minoxidil. The experiment showed that gardenia glycoside could apparently inhibit hair loss caused by chemotherapy agents.
[0095] The results of hair length and weight are as follows Figure 5 , Figure 6 As shown in the figure, compared with the blank control group, the hair length and weight of the model group were significantly reduced, proving that the model was successful. Compared with the model group, the Gardenia glycoside ointment group could significantly increase the hair length and weight, and the effects of the 1.0% and 2.0% Gardenia glycoside groups were better than minoxidil.
[0096] The above experimental results show that Gardenia jasminoides can inhibit hair loss caused by chemotherapy drugs.
[0097] Example 3 Experimental evaluation of the therapeutic effect of geniposide on the androgenic alopecia model of C57BL / 6 mice
[0098] 1. Experimental Animals
[0099] The experimental animals were the same as in Example 1.
[0100] 2. Drug preparation
[0101] The preparation of 4% chloral hydrate and gardenia glycoside ointment is the same as that in Example 1.
[0102] 0.25% testosterone solution: Accurately weigh 0.25g of testosterone powder, add 70ml of anhydrous ethanol solution and 30ml of propylene glycol solution, dissolve completely, and store in a 4℃ refrigerator for later use.
[0103] Blank solvent: 35 ml of anhydrous ethanol solution and 15 ml of propylene glycol solution were evenly mixed to form 50 ml of blank solvent and stored in a 4°C refrigerator for later use.
[0104] 3. Modeling of androgenic alopecia
[0105] (1) Experimental principle:
[0106] The initial stage of establishing the androgenic alopecia model in C57BL / 6 mice is similar to the natural hair growth and hair removal mouse model. Starting from the second day after the back hair of 7-8 week old C57 male mice is removed, 0.25% testosterone solution is used daily to establish the model to inhibit hair growth.
[0107] (2) Specific operations:
[0108] The depilatory method is the same as in Example 1.
[0109] Forty-eight male C57BL / 6J mice were randomly divided into control group, model group, 0.5% gardenia glycoside group, 1.0% gardenia glycoside group, 2.0% gardenia glycoside group, and 2.5% minoxidil group, with 8 mice in each group.
[0110] Starting from the first day after hair removal, the modeling agent was applied to the back of the hair removal area of the mice, 200 μl / mouse, once a day, and the modeling continued for 14 days. The blank control group was applied with blank solvent, and the other groups were applied with 0.25% testosterone solution.
[0111] 4. Experimental study on the efficacy of geniposide in androgenic alopecia model
[0112] After modeling every day, the modeling agent was absorbed and the mice were smeared on the back for medication, once a day for 14 consecutive days. The minoxidil dosage was 200 μl per mouse. The control group and the model group were smeared with a blank cream without drug; the gardenia glycoside ointment group was smeared with a concentration of 0.5%, 1.0%, and 2.0%, and the dosage was 0.2 g / mouse. Each time the ointment was administered, a syringe was used to push out 0.2 ml of the ointment and evenly smeared on the back from the tail to the front.
[0113] On the 15th day after administration, the experimental mice were intraperitoneally injected with 10 μl / g 4% chloral hydrate. After the anesthesia of the mice was stable, the hairs were carefully plucking at 6 fixed points on the back of the mice with tweezers. About 10 hairs were plucking each time and placed on a clean white paper. The length was measured with a vernier caliper and the longest value was selected as the record value. The whole measurement process was repeated twice.
[0114] After the hair length measurement is completed, use a shaver to shave the grown hair in the depilatory area, collect it with weighing paper, and weigh the gross weight with a 1 / 100,000 electronic balance.
[0115] 5. Experimental results
[0116] The results of hair length and weight are as follows Figure 7 , Figure 8 As shown in the figure, compared with the blank control group, the hair length and weight of the model group were significantly reduced, proving that the model was successful. Compared with the model group, the geniposide ointment group increased hair length and weight in a dose-dependent manner, and the effect of the geniposide group was better than that of minoxidil.
[0117] The above experimental results show that Gardenia jasminoides can alleviate hair loss caused by androgen.
[0118] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.
Claims
1. Use of gardenia glycoside and its physiologically acceptable salts or solvates in the preparation of anti-hair loss and hair growth drugs.
2. The use according to claim 1, characterized in that The medicine is used in pharmaceutical preparations; the pharmaceutical preparations are used in preventing, caring for and treating thinning hair, hair loss and promoting hair health and growth.
3. The use according to claim 2, characterized in that: The pharmaceutical preparation comprises geniposide and a physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.
4. The use according to claim 2, characterized in that: The dosage form of the drug is cream, patch, ointment, cream preparation, gel or spray.
5. The use according to claim 2, characterized in that: The dosage form of the drug is tablets, granules, capsules, oral liquid preparations, pills, suspensions or dripping pills.
6. The use according to claim 2, characterized in that: The gardenia glycoside and its physiologically acceptable salt or solvate account for 0.1-10 wt % of the total weight of the preparation.
7. The use according to claim 1, characterized in that The medicine is used for preventing and / or treating hair loss after chemotherapy; the medicine is used for preventing and / or treating androgenic alopecia.
8. The use according to claim 1, characterized in that The medicine is used in cosmetics, care products or beauty products; the cosmetics, care products or beauty products are selected from shampoo, hair conditioner, hair care essence, hair care oil, hair care lotion, scalp cream, hair care gel, hair spray, hair care mask or eyebrow care liquid.
9. The use according to claim 1, characterized in that The drug stimulates hair growth; the stimulation of hair growth includes accelerating the natural growth rate of hair, increasing hair length and weight, and promoting the growth of existing hair in a healthy state; the drug stimulates the expression and synthesis of growth factors, stimulates cell growth, promotes cell survival, and promotes hair growth.
